

• **Name:** Se-Hoon Lee

• **Current Position:** Professor

• **Country:** Korea

• **Educational Background:**

Year	Institute	Position
1996	College of Medicine, Seoul National University, Seoul, Korea	M.D.
2008	Graduate School, Seoul National University, Seoul, Korea	Ph.D.
2001	Seoul National University Hospital, Seoul, Korea	Residency
2002	Seoul National University Hospital, Seoul, Korea	Fellowship
2004	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Fellowship

• **Professional Experience:**

Year	Institute	Position
2005~2015	Seoul National University Hospital, Seoul, Korea	Assistant and Associate Professor
2009~2010	Dana-Farber Cancer Institute, Boston, MA (Harvard Medical School) & Broad Institute, Cambridge, MA	Visiting Scholar
2015~	Samsung Medical Center, Sungkyunkwan University, Seoul, Korea	Professor

• **Professional Organizations:** Samsung Medical Center, Sungkyunkwan University, Seoul, Korea

• **Main Scientific Publications:**

1. Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load. **Nat Commun.** 2019 Sep 19;10(1):4278. [corresponding author]
2. Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. **Eur J Cancer.** 2019 Sep 4;120:65-74. [corresponding author]
3. Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. **J Thorac Oncol.** 2019 Jun 10. [Epub ahead of print] [first author]

4. Zhou C, Kim SW, Reungwetwattana T, Zhou J, Zhang Y, He J, Yang JJ, Cheng Y, Lee SH, Bu L, Xu T, Yang L, Wang C, Liu T, Morcos PN, Lu Y, Zhang L. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. **Lancet Respir Med.** 2019 May;7(5):437-446.
5. Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, Lee SH. Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease. **Int J Cancer.** 2019 Feb 26. [Epub ahead of print] [corresponding author]
6. Kim Y, Lee B, Shim JH, Lee SH, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer. **J Thorac Oncol.** 2018 Oct 31. [corresponding author]